share on
The company aims to grow to a team of 30 in Singapore by 2026, across administrative, commercial, market access, medical affairs, and quality assurance functions.
Daiichi Sankyo Singapore has officially launched in Singapore on 22 February 2024.
As a subsidiary of Daiichi Sankyo Company, Daiichi Sankyo Singapore will be dedicated to bridging unmet needs in oncology, in hopes of extending and improving the lives of cancer patients; in Singapore, cancer accounts for almost 30% of all deaths locally.
The company will focus on antibody-drug conjugates (ADCs), a class of drugs that offer targeted precision and potent drug delivery to certain tumour types, by delivering potent cancer-killing agents directly to cancer cells to eliminate them, whilst limiting damage to healthy surrounding cells.
In response to queries by HRO, a spokesperson from Daiichi Sankyo said the team in Singapore is made up of administrative, commercial, market access, medical affairs and quality assurance functions. It aims to grow to a headcount of 30 across these functions by 2026, to further support the firm's goal of bringing more rapid access and innovation to people living with cancer in Singapore.
Goh Wan Yee, Senior Vice President and Head, Healthcare Division, Singapore Economic Development Board, commented: “Daiichi Sankyo’s decision to set up in Singapore reflects our strength as a global biomedical sciences hub and will further enrich our ecosystem with capabilities in precision therapeutics. We look forward to seeing Daiichi Sankyo’s growth and efforts to bring forth novel drugs that would benefit patients around the world."
Koichi Morino, Managing Director, Daiichi Sankyo Singapore, added: “Singapore has increasingly been becoming an important global hub for precision cancer treatment research and innovation. Therefore, with our proprietary DXd ADC technology, we are excited to contribute to improving outcomes for people living with cancer in Singapore.
“We are committed to creating new employment and treatment opportunities in Singapore, and look forward to close partnership with the relevant professional and patient communities to bring forward new methods of drug delivery.”
As part of the Daiichi Sankyo Quality Assurance organisation, the newly set up research & development, pharmacovigilance, and quality assurance (RDPV QA) function in Singapore "signifies a strategic leap forward in reinforcing the organisation's commitment to patients, customers, and rigorous quality assurance" in all its processes.
This APAC regional hub will be a centre of excellence, driving the mission of 'Patient first, quality Always' while aiming to ensure the highest quality standards in research & development, pharmacovigilance, medical affairs and key processes and systems across the region.
Lead image / Provided
share on
